impact factor, citescore
logo
In press
In Press
Recent issue
Recent issue
Recent Supplement
Recent supplement
archives
Archives
articles free
Free to view
Search
Search
 

Reviews

 

Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives

1, 2, 3, 4, 5, 6

 

  1. Rheumatology Unit, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
  2. Immunology and Allergology Laboratory, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
  3. Rheumatology Unit, P. Dettori Hospital, AST Sardegna, Tempio Pausania, Italy.
  4. Gastroenterology Unit, Internal Medicine Department, ASST Fatebenefratelli-Sacco, Milan University School of Medicine, Milan, Italy.
  5. Immunology and Allergology Laboratory, S. Giovanni di Dio Hospital, Azienda USL-Toscana Centro, Florence, Italy.
  6. Rheumatology Unit, Department of Internal Medicine, ASST Fatebenefratelli-Sacco, Milan University School of Medicine, Milan, Italy. piercarlo.sarziputtini@gmail.com

CER14422
2021 Vol.39, N°1
PI 0196, PF 0202
Reviews

Free to view
(click on article PDF icon to read the article)

PMID: 33555252 [PubMed]

Received: 14/01/2021
Accepted : 22/01/2021
In Press: 05/02/2021
Published: 05/02/2021

Abstract

Since January 2020, the whole world has been facing the worst epidemic for a century. SARS-CoV- 2 infection has so far caused more than one million deaths, with the only measures capable of containing the spread of the virus being social distancing, frequent hand washing, and the wearing of masks. Vaccine development was urgently needed and there are now more than 90 candidate vaccines being developed using different technologies. The European Medicines Agency has recently approved a second mRNA-based vaccine, but the introduction of vaccines has raised some doubts about patients with rheumatic disease, who are at high risk of infection because of disease activity and the therapies used to treat it. The aim of this study was to investigate how vaccines may interact with the immune system and treatment of such patients, and how to monitor the post-vaccine antibody titres and T cell responses in order to assess their efficacy and safety.

DOI: https://doi.org/10.55563/clinexprheumatol/7afn90

Rheumatology Article